Copyright: ©Author(s) 2026.
World J Psychiatry. Apr 19, 2026; 16(4): 114462
Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.114462
Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.114462
Table 2 Depression prevalence and clinical characteristics, mean ± SD
| Indicator | Depression (n = 31) | Non-depression (n = 39) | t/χ2/r | P value |
| Depression cases | 31 | 39 | 9.42 | 0.002a |
| HAM-D | 18.5 ± 4.8 | 8.2 ± 3.1 | 6.85 | < 0.001b |
| BDI-II | 19.1 ± 5.0 | 7.9 ± 2.8 | 7.10 | < 0.001b |
| PDQ-39 total | 52.3 ± 15.7 | 28.4 ± 12.1 | 7.37 | < 0.001b |
| PDQ-39 emotional well-being | 68.2 ± 18.3 | 22.1 ± 14.6 | 11.82 | < 0.001b |
| Correlation with disease duration | 0.412 | 0.180 | 0.412 | 0.001a |
| Correlation with UPDRS I | 0.689 | 0.250 | 0.689 | < 0.001b |
| Correlation with UPDRS III | 0.186 | 0.120 | 0.186 | 0.124 |
| Correlation with H-Y stage | 0.203 | 0.095 | 0.203 | 0.089 |
- Citation: Chen YS, Yang SY, Lu KY, Li M, Liu T, Zhu SG, Lu HL, Hu K. Serum 5-hydroxytryptamine levels as biomarkers for motor dysfunction and depression in Parkinson’s disease patients. World J Psychiatry 2026; 16(4): 114462
- URL: https://www.wjgnet.com/2220-3206/full/v16/i4/114462.htm
- DOI: https://dx.doi.org/10.5498/wjp.v16.i4.114462